Difference between revisions of "Vincristine liposomal (Marqibo)"
m |
|||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[B-cell acute lymphoblastic leukemia]] |
| − | *[[ | + | *[[Diffuse large B-cell lymphoma]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 38: | Line 32: | ||
[[Category:Vinca alkaloids]] | [[Category:Vinca alkaloids]] | ||
| − | [[Category: | + | [[Category:B-cell acute lymphoblastic leukemia medications]] |
| − | [[Category: | + | [[Category:Diffuse large B-cell lymphoma medications]] |
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 02:06, 20 July 2017
General information
Class/mechanism: Vinca alkaloid which causes cell cycle arrest in metaphase and inhibits mitosis. Vincristine stabilizes the spindle apparatus by binding to tubulin, alters microtubule structure and function, and inhibits chromosome separation. Marqibo is a formulation of vincristine sulfate that is encapsulated in sphingomyelin/cholesterol liposomes (Optisomes), which are hypothesized to provide improved tissue drug penetration and reduced toxicity.[1][2][3][4]
Route: IV
Extravasation: irritant/vesicant (depending on reference)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information is available in the Vincristine liposomal (Marqibo) package insert.[1]
- Vincristine liposomal (Marqibo) patient drug information (Chemocare)[5]
History of changes in FDA indication
- 8/9/2012: FDA approved "for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies."[1]
Also known as
Vincristine sulfate liposome injection, VSLI.
References
- ↑ 1.0 1.1 1.2 1.3 Vincristine liposomal (Marqibo) package insert
- ↑ Vincristine liposomal (Marqibo) package insert (locally hosted backup)
- ↑ Marqibo manufacturer's website
- ↑ Jeffrey A. Silverman, Walter Aulitzky, John Lister, Lori Maness, Gary Schiller, Karen Seiter, Scott E. Smith, Wendy Stock, Dina Ben Yehuda, Steven R. Deitcher. Marqibo® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). ASH 2010 abstract 2142. link to abstract
- ↑ Vincristine liposomal (Marqibo) patient drug information (Chemocare)